New developments in the use of apheresis to collect haematopoietic cells for cell transplantation and cell therapies. (29th January 2016)

• Record Type: Journal Article
• Authors: Granata, A.; Drezet, A.; Faucher, C.; Lemarie, C.; Calmels, B.; Chabannon, C.
• Is Part Of: ISBT science series. Volume 11(2016)Supplement 1
• Page Start: 100
• Page End: 104
• Publication Date: 2016-01-29
• Subjects: aphereses -- cell collection -- cell manufacturing -- cell processing -- cell procurement -- hematopoietic stem cell transplantation; Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/voxs.12208
• Languages: English
• ISSNs: 1751-2816

Abstract

Abstract : Currently, there is renewed interest in apheresis as a tool to collect blood mononuclear cells. Several manufacturers have introduced a new generation of cell separators. Historical applications, that is the collection of autologous or allogeneic hematopoietic stem and progenitor cells for 'bone marrow transplantation', witness new developments: introduction of new agents that mobilize stem cells help deal with 'poor mobilizers' and streamline the collection process, algorithms based on robust measurement of circulating and collected CD34 + cells allow to tailor the collection procedure to better suit donors and recipients' needs. Furthermore, new forms of cellular therapies are being developed, with potential applications as additions, substitutes or unrelated to conventional hematopoietic stem cell transplantation. These are mostly immune therapies that will be manufactured from blood mononuclear cells; these will be efficiently engineered only when the collected cell product meets predefined specifications that are likely to be different and more stringent than they are for the collection of minimally manipulated autologous or allogeneic blood grafts. Thus, healthcare professionals who perform or supervise apheresis will need to update and upgrade their skills and competencies in the near future.